Testing and Treating Hepatitis C in Community Pharmacies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

356 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C Virus, (HCV), infection is a major health concern in the UK with up to 0.7% of the population infected. At best, 25% of those infected will clear the infection spontaneously, though for those who develop a chronic infection, they may go onto to develop liver cirrhosis or liver cancers.

The standard of care within the NHS is that patients with a history of intravenous drug use or those currently on methadone are at high risk of having HCV infection and should be offered HCV testing. Once diagnosed they can be referred to nurse led treatment pathways. Less than 10% of the methadone users are even tested for HCV and of them fewer than 20% go onto treatment regimens that successfully clear the infection despite regular interactions with heath care staff.

Pharmacists who have daily interactions with patients receiving methadone are ideally placed to deliver anti HCV therapy as they have daily contact with this client group and are well placed to advise on the drug therapy.

The SuperDOT C study will examine the impact of pharmacy led Directly Observed Therapy (DOT) for HCV treatment in patients attending Community Pharmacies in participating Health Boards within NHS Scotland. The impact of this approach will be compared with those referred to standard care pathways on how well participants clear their HCV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ask a Friend to Take a Test for Hepatitis C Infection

NCT03697135

Hepatitis C

COMPLETED

Hepatitis C Pharmacy-based Strategy for Injectors

NCT04698629

Hepatitis C

COMPLETED

Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy

NCT03483818

Hepatitis C

COMPLETED NA

Pharmacist-led Hepatitis C Management

NCT04322981

Hepatitis C Virus Infection

UNKNOWN PHASE4

Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV

NCT03356405

Hepatitis C Viral

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SuperDOT-C study will evaluate a new pathway of care for patients on OST who are already receiving OST therapy on a daily basis from a pharmacist. Newer therapies for HCV have recently become much simpler to initiate and supervise with much improved effectiveness and as described below it is now proposed to extend the role of community pharmacists into initiating HCV therapy alongside the existing OST The SuperDOT-C study will utilise this existing environment and relationship to smooth the pathway into HCV therapy with co-administration of OST alongside the anti-HCV therapy under the supervision of the pharmacist compared with the established pathway of referral to another site and treatment with a nurse led ant-HCV treatment program. This new pathway may have positive effects on the movement towards HCV cure at multiple levels. The planned pathway is different to current care at each point, from testing and diagnosis through adherence to cure. In the planned pathway, the patient interacts with the pharmacist on a daily basis, as compared to intermittent interaction with a secondary care team member. The result being that the patient has a shorter care pathway, with less travelling and better access to anti-HCV treatment. The daily interaction with the pharmacy provides opportunities to assess and support the patient, provide sound advice and care, with the added benefit of being able to directly observe treatment, (DOT), thus potentially improving adherence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacist Led

This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists

Group Type EXPERIMENTAL

Pharmacist Led

Intervention Type OTHER

Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects

Nurse Led

This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses

Group Type EXPERIMENTAL

Nurse led

Intervention Type OTHER

Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist Led

Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects

Intervention Type OTHER

Nurse led

Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HCV PCR positive,
* Stable OST dose for greater than 12 weeks prior to study enrolment

Exclusion Criteria

* Evidence of current or previous decompensated liver disease,
* Currently receiving HCV eradication treatment
* HIV infection,
* HBsAg positive with detectable HBV DNA,
* Pregnancy
* Cirrhosis or high fibrosis score
* Genotype deemed unsuitable for treatment with available study drugs
* Unable or unwilling to provide informed consent

Eligible Sex

ALL

Accepts Healthy Volunteers

No